Medpace Holdings, Inc. logo
Medpace Holdings, Inc. (MEDP)
Compare

Medpace Holdings, Inc. (MEDP) EV/Sales Ratio: 4.79x

popular:market cap|pe ratio|revenue|price history|total return

Is Medpace Holdings, Inc.’s EV/Sales ratio high or low?

Medpace Holdings, Inc.'s EV/Sales ratio of 4.79x is 11% below its 5-year average of 5.40x, near the low end of its 5-year range (3.94x–7.76x).

As of Wednesday, June 17, 2026. 20.36% below its 12-month average of 6.01x.

EV/EBITDA|P/S Ratio|Revenue|All Metrics

MEDP EV/Sales Ratio Chart

MEDP EV/Sales Ratio
4.79x+13.78% 1Y
Zoom

MEDP Average EV/Sales Ratio Chart

MEDP Current vs Average EV/Sales Ratio Chart

MEDP EV/Sales Ratio Metrics

EV/SALES RATIO

4.79x

EV/SALES RATIO AVG TTM

6.01x

EV/SALES RATIO AVG 3Y

5.55x

EV/SALES RATIO AVG 5Y

5.40x

EV/SALES RATIO AVG 10Y

4.69x

EV/SALES RATIO AVG 15Y

N/A

EV/SALES RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

-20.36%

CURRENT VS 3Y AVG

-13.69%

CURRENT VS 5Y AVG

-11.23%

CURRENT VS 10Y AVG

+2.19%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

MEDP Competitors' EV/Sales Ratio

NAMEMARKET CAPEV/SALES RATIOTTM3Y5Y
Medpace Holdings, Inc. (MEDP)$13.18B4.79x6.01x5.55x5.40x
The Cooper Companies, Inc. (COO)vs ›$13.14B3.65x4.14x5.15x5.80x
Solventum Corporation (SOLV)vs ›$13.26B2.17x2.19x2.26x2.26x
DaVita Inc. (DVA)vs ›$13.46B1.94x1.81x1.84x1.85x
Align Technology, Inc. (ALGN)vs ›$12.86B2.91x2.72x4.05x5.88x
Revvity, Inc. (RVTY)vs ›$11.29B4.76x4.79x5.56x5.57x
Walgreens Boots Alliance, Inc. (WBA)vs ›$10.37B0.25x0.26x0.37x0.45x
Baxter International Inc. (BAX)vs ›$10.19B1.61x1.71x2.16x2.63x
Hologic, Inc. (HOLX)vs ›$16.97B4.25x4.02x4.39x4.15x
Charles River Laboratories International, Inc. (CRL)vs ›$8.90B2.96x2.80x3.02x3.78x

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

  • It works for unprofitable companies where P/E doesn't apply
  • Revenue is harder to manipulate than earnings
  • It supports comparisons across companies at different profitability stages
  • It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

Medpace Holdings, Inc. EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Medpace Holdings, Inc. EV/Sales Ratio FAQ

What is the EV/Sales ratio for Medpace Holdings, Inc. (MEDP)?
The EV/Sales ratio for MEDP stock is 4.79x.
Is Medpace Holdings, Inc.'s EV/Sales ratio high or low?
Medpace Holdings, Inc.'s EV/Sales ratio of 4.79x is 11% below its 5-year average of 5.40x, near the low end of its 5-year range (3.94x–7.76x).
What is the TTM average EV/Sales ratio for Medpace Holdings, Inc. (MEDP)?
The TTM average EV/Sales ratio for MEDP stock is 6.01x.
What is the 3Y average EV/Sales ratio for Medpace Holdings, Inc. (MEDP)?
The 3Y average EV/Sales ratio for MEDP stock is 5.55x.
What is the 5Y average EV/Sales ratio for Medpace Holdings, Inc. (MEDP)?
The 5Y average EV/Sales ratio for MEDP stock is 5.40x.
What is the 10Y average EV/Sales ratio for Medpace Holdings, Inc. (MEDP)?
The 10Y average EV/Sales ratio for MEDP stock is 4.69x.

Medpace Holdings, Inc. EV/Sales Ratio History

DATEEV/SALES RATIO
2026-06-164.79x
2026-06-154.86x
2026-06-124.86x
2026-06-114.94x
2026-06-104.84x
2026-06-094.85x
2026-06-084.75x
2026-06-054.71x
2026-06-044.76x
2026-06-034.68x
2026-06-024.62x
2026-06-014.68x
2026-05-294.64x
2026-05-284.65x
2026-05-274.43x
2026-05-264.44x
2026-05-224.48x
2026-05-214.45x
2026-05-204.36x
2026-05-194.34x
2026-05-184.35x
2026-05-154.29x
2026-05-144.33x
2026-05-134.38x
2026-05-124.34x
2026-05-114.31x
2026-05-084.39x
2026-05-074.44x
2026-05-064.42x
2026-05-054.46x
2026-05-044.31x
2026-05-014.32x
2026-04-304.33x
2026-04-294.27x
2026-04-284.23x
2026-04-274.36x
2026-04-244.24x
2026-04-234.06x
2026-04-225.72x
2026-04-215.80x
2026-04-205.95x
2026-04-175.86x
2026-04-165.81x
2026-04-155.84x
2026-04-145.86x
2026-04-135.64x
2026-04-105.55x
2026-04-095.64x
2026-04-085.86x
2026-04-075.72x
2026-04-065.58x
2026-04-025.61x
2026-04-015.51x
2026-03-315.40x
2026-03-305.17x
2026-03-275.07x
2026-03-265.24x
2026-03-255.25x
2026-03-245.18x
2026-03-235.13x
2026-03-205.08x
2026-03-195.18x
2026-03-185.11x
2026-03-175.11x
2026-03-165.10x
2026-03-135.06x
2026-03-124.98x
2026-03-115.37x
2026-03-105.25x
2026-03-095.38x
2026-03-065.29x
2026-03-055.28x
2026-03-045.24x
2026-03-035.23x
2026-03-025.14x
2026-02-275.07x
2026-02-265.02x
2026-02-254.92x
2026-02-244.96x
2026-02-235.00x
2026-02-205.10x
2026-02-195.01x
2026-02-185.01x
2026-02-174.80x
2026-02-134.80x
2026-02-124.67x
2026-02-114.76x
2026-02-105.01x
2026-02-096.62x
2026-02-066.77x
2026-02-056.76x
2026-02-047.01x
2026-02-037.10x
2026-02-027.35x
2026-01-307.28x
2026-01-297.41x
2026-01-287.47x
2026-01-277.53x
2026-01-267.52x
2026-01-237.35x
2026-01-227.58x
2026-01-217.76x
2026-01-207.53x
2026-01-167.64x
2026-01-157.73x
2026-01-147.71x
2026-01-137.60x
2026-01-127.49x
2026-01-097.44x
2026-01-087.50x
2026-01-077.66x
2026-01-067.61x
2026-01-057.33x
2026-01-027.13x
2025-12-317.02x
2025-12-307.11x
2025-12-297.12x
2025-12-267.09x
2025-12-247.14x
2025-12-237.12x
2025-12-227.14x
2025-12-197.10x
2025-12-187.00x
2025-12-176.96x
2025-12-166.98x
2025-12-156.98x
2025-12-126.97x
2025-12-117.07x
2025-12-107.00x
2025-12-096.79x
2025-12-086.86x
2025-12-056.85x
2025-12-046.80x
2025-12-037.20x
2025-12-027.29x
2025-12-017.35x
2025-11-287.40x
2025-11-267.58x
2025-11-257.65x
2025-11-247.73x
2025-11-217.40x
2025-11-207.32x
2025-11-197.40x
2025-11-187.37x
2025-11-177.32x
2025-11-147.37x
2025-11-137.39x
2025-11-127.47x
2025-11-117.53x
2025-11-107.50x
2025-11-077.36x
2025-11-067.40x
2025-11-057.48x
2025-11-047.43x
2025-11-037.42x
2025-10-317.31x
2025-10-307.25x
2025-10-297.30x
2025-10-287.25x
2025-10-277.45x
2025-10-247.56x
2025-10-237.46x
2025-10-227.44x
2025-10-217.42x
2025-10-207.40x
2025-10-177.18x
2025-10-167.09x
2025-10-157.00x
2025-10-147.03x
2025-10-137.17x
2025-10-106.82x
2025-10-097.06x
2025-10-087.22x
2025-10-077.23x
2025-10-067.21x
2025-10-037.24x
2025-10-027.29x
2025-10-017.40x
2025-09-307.00x
2025-09-296.81x
2025-09-266.76x
2025-09-256.64x
2025-09-246.77x
2025-09-236.75x
2025-09-226.78x
2025-09-196.79x
2025-09-186.83x
2025-09-176.78x
2025-09-166.68x
2025-09-156.76x
2025-09-126.68x
2025-09-116.77x
2025-09-106.49x
2025-09-096.61x
2025-09-086.70x
2025-09-056.63x
2025-09-046.57x
2025-09-036.55x
2025-09-026.44x
2025-08-296.47x
2025-08-286.44x
2025-08-276.45x
2025-08-266.39x
2025-08-256.36x
2025-08-226.31x
2025-08-216.17x
2025-08-206.34x
2025-08-196.29x
2025-08-186.30x
2025-08-156.23x
2025-08-146.25x
2025-08-136.37x
2025-08-126.25x
2025-08-116.13x
2025-08-085.92x
2025-08-075.84x
2025-08-065.86x
2025-08-055.94x
2025-08-045.89x
2025-08-015.76x
2025-07-315.82x
2025-07-305.96x
2025-07-296.10x
2025-07-286.17x
2025-07-256.09x
2025-07-246.21x
2025-07-235.96x
2025-07-226.50x
2025-07-214.32x
2025-07-184.37x
2025-07-174.47x
2025-07-164.41x
2025-07-154.38x
2025-07-144.49x
2025-07-114.53x
2025-07-104.60x
2025-07-094.50x
2025-07-084.52x
2025-07-074.47x
2025-07-034.50x
2025-07-024.57x
2025-07-014.50x
2025-06-304.39x
2025-06-274.35x
2025-06-264.29x
2025-06-254.35x
2025-06-244.41x
2025-06-234.32x
2025-06-204.33x
2025-06-184.23x
2025-06-174.16x
2025-06-164.21x
2025-06-134.17x
2025-06-124.25x
2025-06-114.23x
2025-06-104.28x
2025-06-094.17x
2025-06-064.14x
2025-06-054.10x
2025-06-044.38x

Showing the most recent 260 of 2,475 data points. The chart above shows the full history.

Related Metrics

EV/EBITDAP/S RatioRevenueAll Metrics

About Medpace Holdings, Inc.

Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.

Cincinnati, OH
5,900 employees
www.medpace.com
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
August James Troendle
View full financials